AMGN

Amgen Inc. at a Glance: What the Business Does Amgen Inc. (AMGN) is a prominent player in the global healthcare sector, specializing in the discovery, development, manufacturing, and delivery of human therapeutics. The company operates primarily within the Drug Manufacturers - General industry, with a focus on critical areas such as inflammation, oncology, hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Key products include Enbrel, which treats autoimmune diseases like plaque psoriasis and rheumatoid arthritis, and Neulasta, designed to mitigate infection risks in cancer patients. Amgen's competitive advantage lies in its robust pipeline and established market presence, bolstered by a strong portfolio of biologics and innovative therapies. As of 2023, Amgen employs approximately 28,000 people and boasts a market capitalization of $224.20 billion, reflecting its significant role in the biopharmaceutical space. Unique to Amgen is its commitment to leveraging biotechnology to address unmet medical needs, positioning the company as a leader in the ongoing evolution of drug development. Breaking Down AMGN's Financials: Revenue, Margins & EPS Amgen's financial trajectory has shown a commendable upward trend, with revenue climbing to $36.75 billion in the latest fiscal year, up from $33.42 billion the previous year. Over the past three years, revenue has increased from $28.19 billion in 2021 to the current figure, reflecting a compound annual growth rate (CAGR) of approximately 14.5%. The company's gross profit stands at $24.71 billion, resulting in a robust gross margin of 67.2%. Operating income is reported at $9.08 billion, with an operating margin of 24.7%, indicative of solid operational efficiency. Net income has surged to $7.71 billion, leading to a net margin of 21.0%, and earnings per share (EPS) have reached $14.23, showcasing an impressive growth trajectory. This performance is further emphasized by the EBITDA of $14.25 billion, reinforcing Amgen's ability to generate substantial earnings before interest, taxes, depreciation, and amortization. AMGN Balance Sheet Check: Debt, Cash & Liquidity Assessing Amgen's balance sheet reveals a complex picture of financial health. The company holds total assets of $90.59 billion against total liabilities of $81.93 billion, resulting in shareholders' equity of $8.66 billion. However, the total debt of $54.60 billion raises concerns, particularly given the debt-to-equity ratio of 6.31, suggesting a highly leveraged position. On the liquidity front, Amgen's current ratio stands at 1.14, which is slightly above the threshold of 1, indicating that the company can meet its short-term obligations. With cash reserves of $9.13 billion and a net debt position of $45.48 billion, the balance sheet appears strained due to the substantial debt load. The reliance on debt could pose risks if interest rates rise or if operational performance falters, making it imperative for investors to monitor these financial metrics closely. Where Does AMGN's Cash Go? A Capital Allocation Review Amgen's capital allocation strategy reflects its focus on maintaining strong cash flow generation. The company reported an operating cash flow of $9.96 billion, which supports its ability to fund operations and invest in growth initiatives. However, free cash flow has decreased by 22.1% year-over-year, now at $8.10 billion, which raises questions about sustainability, especially as capital expenditures totaled $1.86 billion. Amgen has returned $5.12 billion to shareholders through dividends, although the absence of stock buybacks indicates a cautious approach to capital deployment. This reliance on dividends may appeal to income-focused investors, but the declining free cash flow could limit future dividend growth. Overall, while Amgen demonstrates strong cash flow generation, the decreasing free cash flow trend warrants attention. AMGN Valuation: Expensive, Cheap, or Fairly Priced? Valuation metrics for Amgen present a mixed picture when compared to its peers in the healthcare sector. The company currently trades at a price-to-earnings (P/E) ratio of 29.14, which is relatively high and suggests that investors are pricing in significant growth expectations. The price-to-book (P/B) ratio stands at 25.90, indicating a premium valuation compared to the industry average. With a price-to-sales (P/S) ratio of 6.10, Amgen appears expensive relative to its revenue generation capabilities. The enterprise value to EBITDA (EV/EBITDA) ratio of 18.93 further supports the notion that the stock is trading at a premium. These valuation metrics imply that while Amgen has strong growth potential, investors should be cautious of overpaying for future growth, particularly given the high debt levels and potential market volatility. Catalysts Ahead: AMGN's Growth Outlook & Analyst Estimates Looking forward, Amgen's growth outlook is influenced by several key factors, although specific analyst estimates are currently unavailable. The company's robust drug pipeline and ongoing research initiatives are expected to drive future revenue growth. The expansion into new therapeutic areas and potential market opportunities could provide additional revenue streams. However, the lack of recent earnings data complicates the assessment of near-term performance. Amgen's historical earnings surprises track record suggests that it has occasionally exceeded market expectations, but the absence of forward guidance raises uncertainty. Investors would benefit from closely monitoring developments in Amgen's pipeline and any strategic partnerships that could enhance growth prospects. AMGN Investment Risks Worth Knowing About Investors should remain vigilant regarding several specific risks associated with Amgen. The company's high debt burden of $54.60 billion poses a significant risk, particularly in an environment of rising interest rates, which could increase borrowing costs. Margin compression is another concern, as increasing competition in the biopharmaceutical sector may pressure pricing and profitability. Additionally, regulatory risks are inherent in the healthcare industry, where changes in policy or drug approval processes can impact revenue streams. The stock's beta of 0.43 indicates lower volatility compared to the broader market, yet this does not eliminate exposure to macroeconomic sensitivities that could affect demand for Amgen's products. As such, these risk factors warrant careful consideration when evaluating the investment thesis for AMGN. 2026 Outlook: Is Amgen Inc. Stock Worth Owning? In synthesizing the various aspects of Amgen's performance and outlook, the stock presents a complex investment case. While the company boasts strong revenue growth and a solid market position, its high debt levels and declining free cash flow raise concerns about long-term sustainability. AMGN may appeal to growth-oriented investors looking for exposure to the healthcare sector, particularly given its innovative product pipeline. However, value investors may find the current valuation metrics less attractive, given the company's premium pricing and potential risks. Overall, Amgen Inc. could be a suitable investment for those willing to accept a higher risk profile in exchange for potential growth in the biopharmaceutical space. Investors should closely monitor financial performance, particularly cash flow trends and debt levels, as these will be critical in determining the stock's future trajectory.

Financial figures come from Amgen Inc.'s latest annual SEC filing (fiscal year 2025), so they can lag recent quarters. Prices are delayed up to 15 minutes.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple

Frequently Asked Questions about AMGN